Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To confirm that the hypothesis that UK-427,857 added to Optimised Background Therapy (OBT) provides an additional reduction in plasma HIV-1 RNA compared to OBT alone, as measured by the difference between each of the two UK-427,857 regimens versus the placebo regimen in the mean changes from baseline in plasma HIV-1 RNA at week 24.
Critère d'inclusion
- UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in individuals HIV-1 positive